title: [The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization].
abstract: BACKGROUND
  Administration of enoxaparin to patients with acute coronary syndromes can result in better outcomes in comparison to patients treated with unfractionated heparin. Use of enoxaparin during percutaneous coronary interventions (PCI) can also improve the outcome. Administration of ticlopidine and aspirin for a few days before PCI decreases frequency of ischaemic complications. There is lack of data about safety and efficacy of combined administration of enoxaparin, ticlo-pidine and aspirin during PCI.
  
  
  METHODS
  61 patients with coronary artery disease were involved in the study. All patients were pretreated with aspirin (75-325 mg/d) and ticlopidine (2 x 250 mg) for at least 3 days before PCI. PCI procedures were conducted after i.v. administration of 1 mg/kg of enoxaparin. After PCI bleeding and ischaemic complications were monitored.
  
  
  RESULTS
  In the treated group, no major bleeding occurred, while minor bleeding was noted in 6.5% of patients. No periprocedural major adverse cardiac events (death, Q wave infarction, urgent revascularisation) were observed. Microembolisation was present in 4.9% patients (expressed as CK-MB > 3 times the reference level).
  
  
  CONCLUSIONS
  Intravenous administration of enoxaparin 1 mg/kg during PCI in patients pretreated with aspirin and ticlopidine for at least 3 days before intervention appears to be safe. Safety and high efficacy of enoxapirine in this pilot trial justify initiating the randomized, multicenter trial comparing use of low molecular weight heparin to unfractionated heparin during PCI.
authors.affiliation: II Klinika Kardiologii Instytutu Kardiologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie Kierownik Kliniki, II Klinika Kardiologii Instytutu Kardiologii CMUJ ul. Kopernika 17, 31-501 Kraków.
authors.forename: D
authors.initials: D
authors.lastname: Dudek
authors.forename: P
authors.initials: P
authors.lastname: Zymek
authors.forename: S
authors.initials: S
authors.lastname: Bartuś
authors.forename: J S
authors.initials: JS
authors.lastname: Dubiel
mesh_terms: D000287:Administration, Topical; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006034:Glycyrrhetinic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011300:Preoperative Care; D013988:Ticlopidine / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D013988:Ticlopidine; D006034:Glycyrrhetinic Acid